Home › Non-Small Cell Lung Cancer › Illinois › Joliet
Non-Small Cell Lung Cancer clinical trials in Joliet, IL
12 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Joliet (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi away
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi away
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi away
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RecruitingPhase 2
- Hope and Healing Clinical Research, New Lenox · 6 mi away
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi away
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- University of Chicago, New Lenox · 6 mi away
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi away
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi away
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Joliet
- Lung Cancer12 studies
- Metastatic Cancer7 studies
- Bladder Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Prostate Cancer5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Acute Myeloid Leukemia5 studies
- Breast Cancer4 studies
- Colon Cancer4 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.